Definium Therapeutics Financials - Benzinga

Definium Therapeutics Inc

DFTXNASDAQ

Trade with Public

Trade with Public

$37.36

-0.29-0.77%

Ult. Agg.: Sep 24, 9:27 AM

Panoramica Notizie Previsioni utili Eventi Obiettivi di prezzoDati finanziariSentiment Azionariato Confronta Opzioni Rapporto azionario

Definium Therapeutics Financials

Definium Therapeutics (DFTX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Definium Therapeutics Q2 EPS $(1.44) Misses $(0.55) Estimate

Benzinga Newsdesk

PRO
Definium Therapeutics Q1 EPS $(0.71) Misses $(0.48) Estimate. Cash And Equivalents Of $373.4M

Definium Therapeutics (NASDAQ:DFTX) reported quarterly losses of $(0.71) per share which missed the analyst consensus estimate of $(0.48) by 47.92 percent. This is a 102.86 percent decrease over losses of $(0.35) per

Benzinga Newsdesk

PRO
Definium Therapeutics Q4 EPS $(0.50) Misses $(0.46) Estimate.

Definium Therapeutics (NASDAQ:DFTX) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $(0.46) by 7.76 percent. This is a 21.95 percent decrease over losses of $(0.41) per share

Benzinga Newsdesk

Earnings Scheduled For February 26, 2026

Benzinga Insights

Earnings Preview For Definium Therapeutics

Benzinga Insights

© 2026 Benzinga | All Rights Reserved